Stocks breaking to new annual highs
S&P 500 oversold value screener
Relative strength momentum leaders
Upcoming earnings dates & reports
Filter and sort all 500 stocks
Continuous multi-factor scoring & catalyst forensics
Today's biggest gainers and losers
Quest Diagnostics is the largest clinical laboratory testing provider in the US, operating ~2,200 patient service centers and processing ~500,000 specimens daily across routine diagnostics (blood work, urinalysis), anatomic pathology, and specialized testing. The company benefits from scale advantages in specimen logistics, lab automation, and payer contracting, with ~60% of revenue from commercial insurance and ~20% from Medicare/Medicaid.
Quest operates a hub-and-spoke model with regional laboratories processing high-volume routine tests at low unit costs ($2-5 per test) and specialized reference labs handling complex esoteric tests at premium pricing ($50-500+ per test). Revenue is primarily fee-for-service from third-party payers based on negotiated fee schedules. Competitive advantages include: (1) density of 2,200+ patient service centers creating geographic barriers to entry, (2) scale-driven unit cost advantages through automation and specimen batching, (3) proprietary test menu breadth (3,500+ tests) that competitors cannot replicate, and (4) embedded relationships with 50% of US physicians. Pricing power is moderate - commercial payer rates grow 1-2% annually while Medicare rates are flat to down, offset by mix shift toward higher-reimbursed specialty testing.
Organic test volume growth (excluding COVID testing) - driven by physician visit trends, elective procedure volumes, and diagnostic utilization rates
Revenue per requisition trends - reflects mix shift toward higher-value esoteric/gene-based testing versus routine panels
Payer reimbursement rate changes - particularly commercial rate negotiations and Medicare PAMA rate cuts
Operating margin expansion - driven by Invigorate cost savings program ($150M+ target), lab consolidation, and automation investments
Capital deployment - M&A activity (tuck-in lab acquisitions at 6-8x EBITDA), share repurchases ($1B+ annually), and dividend growth
Medicare PAMA rate cuts - Clinical Laboratory Fee Schedule faces ongoing 0-2% annual reductions under the Protecting Access to Medicare Act, pressuring ~20% of revenue with limited ability to offset through efficiency
Vertical integration by UnitedHealth/Optum and CVS/Aetna - Payers directing testing to captive labs (Optum owns 30+ labs) threatens 15-20% of commercial volume over 5-10 years, particularly in high-margin specialty testing
At-home and point-of-care testing disruption - Consumer-initiated testing and decentralized diagnostics could disintermediate 5-10% of routine testing volumes, though Quest is investing in digital patient engagement
Laboratory Corporation of America (Labcorp) duopoly competition - Two players control 45% of US market, leading to periodic price competition for large health system and payer contracts
Hospital outreach lab competition - Large health systems (Mayo, Cleveland Clinic) expanding reference lab services to capture high-margin esoteric testing, particularly in oncology and genetics where Quest earns 25-30% margins
Debt refinancing risk - $5.5B debt with weighted average maturity of 8-10 years; rising rates increase cost of refinancing $500-800M annual maturities
Pension and post-retirement obligations - Underfunded defined benefit plans create $200-300M potential cash funding requirements if discount rates decline or equity returns disappoint
low-to-moderate - Routine diagnostic testing is non-discretionary and driven by chronic disease management, making ~70% of revenue recession-resistant. However, elective procedures, employer health screenings, and wellness testing (~15-20% of revenue) correlate with employment levels and consumer confidence. Volume typically declines 2-4% in recessions as patients delay non-urgent testing and lose employer-sponsored insurance coverage.
Moderate sensitivity through two channels: (1) $5.5B debt load (0.96x D/E) creates ~$200M annual interest expense - rising rates increase refinancing costs and reduce FCF available for buybacks; (2) as a defensive healthcare stock with 2.1% dividend yield, Quest competes with fixed income for income-focused investors - rising 10-year Treasury yields above 5% historically compress valuation multiples by 1-2 turns. Partially offset by floating-rate debt hedges.
Moderate exposure to commercial insurance bad debt and uninsured patient volumes. During recessions, uninsured patient mix rises from ~5% to 7-8% of volume, increasing bad debt expense by 20-30bps of revenue. Additionally, high-deductible health plan penetration (now 50%+ of commercial lives) creates patient payment collection challenges, though Quest has improved point-of-service collection rates to ~40%.
value and dividend - Quest trades at 14.6x EV/EBITDA (10-15% discount to S&P 500) and offers 2.1% dividend yield with 13.9% ROE, attracting defensive healthcare investors seeking stable cash flow generation. The 5.9% FCF yield and consistent $1.4B annual free cash flow support $400M dividends and $1B+ buybacks, appealing to total return investors. Limited to mid-single-digit organic growth caps appeal to growth investors.
low - Beta of approximately 0.7-0.8 reflects defensive healthcare characteristics. Stock typically declines 10-15% during market corrections versus 20%+ for S&P 500, as diagnostic testing volumes prove resilient. Volatility spikes occur around Medicare rate announcements and large payer contract renewals.
